IMAB News
Archived Headlines
- US IPO Week Ahead: The 2020 US IPO market debuts with a 5-IPO week 01/10/20
- US IPO Week Ahead: The US IPO pipeline is ready to burst entering the New Year 01/03/20
- Chinese immunotherapy biotech I-Mab Biopharma sets terms for $100 million US IPO 01/03/20
- US IPO Weekly Recap: More deals price down in a 3-IPO week 11/01/19
- Chinese immunotherapy biotech I-Mab Biopharma files for a $100 million US IPO 10/29/19
US IPO Week Ahead: GoHealth takes the lead in a 9 IPO Week
Updated Monday, 7/13. Nine IPOs and one SPAC plan to raise $1.5 billion in the week ahead, led by health insurance marketplace GoHealth (GOCO). More deals could join the IPO calendar in the week ahead, including Apple workflow...read more
Burning Up: Hot Streak for Biotechs Continues in 2020
The active market for biotech IPOs looks like it's going to continue in 2020. The latest to go public, preclinical gene therapy biotech Beam Therapeutics (BEAM) upsized its share offering by 69%, priced at the high end of the range, and...read more
US IPO Weekly Recap: 3 Chinese companies and a mortgage lender kick off the 2020 US IPO market
Three Chinese issuers and a mortgage lender entered the public market this past week. All four priced below the midpoint. A German issuer and a SPAC submitted initial filings. Chinese property management company Phoenix Tree Holdings (DNK)...read more
I-Mab Biopharma prices US IPO at $14, within the range
I-Mab, a late-stage cancer/autoimmune biotech developing in-licensed antibodies in China, raised $104 million by offering 7.4 million ADSs at $14, within the range of $12 to $15. I-Mab plans to list on the Nasdaq under the symbol IMAB. Jefferies and CICC acted...read more